Aaron Kesselheim (Scott Eisen/AP Images for AIDS Healthcare Foundation)

Ma­jor Mass­a­chu­setts hos­pi­tals de­cide against us­ing Bio­gen's Aduhelm, with the help of a for­mer FDA ad­comm mem­ber

Har­vard’s Brigham and Women’s Hos­pi­tal, Mass­a­chu­setts Gen­er­al Hos­pi­tal and oth­er af­fil­i­at­ed hos­pi­tals with Mass Gen­er­al Brigham, the state’s largest health care provider, have de­cid­ed to not ad­min­is­ter Bio­gen’s new con­tro­ver­sial Alzheimer’s drug Aduhelm, serv­ing up an­oth­er blow to the drug’s lack­lus­ter launch.

Mass Gen­er­al Brigham came to its de­ci­sion on the lo­cal com­pa­ny’s drug af­ter an ex­ten­sive re­view of its ben­e­fits and risks with the help of ex­perts like Aaron Kessel­heim, a Har­vard pro­fes­sor and physi­cian who was the third mem­ber to re­sign from the FDA ad­vi­so­ry com­mit­tee af­ter FDA signed off on ad­u­canum­ab even as the ad­comm unan­i­mous­ly called on FDA not to ap­prove it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.